{
  "docId": "019de070-7de1-7343-8d2f-5d51a9877c50",
  "docSlug": "ff3158b4501b6094038126272ca46097",
  "documentTitle": "BioAtla | IPO Presentation Deck | 31 slides",
  "authorId": "bioatla",
  "authorName": "BioAtla",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investment_bank",
  "sourceTypeLabel": "Investment bank",
  "presentationDate": "2020-12-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.3333334,
  "pageNumber": 14,
  "pageCount": 31,
  "prevPage": 13,
  "nextPage": 15,
  "slideType": "peer_benchmark",
  "function": "compare_peers",
  "density": "balanced",
  "nDataPoints": 18,
  "notes": "Includes clinical trial safety data and comparative toxicity analysis.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de070-7de1-7343-8d2f-5d51a9877c50/14",
  "deckHref": "/decks/019de070-7de1-7343-8d2f-5d51a9877c50",
  "deckJsonHref": "/decks/019de070-7de1-7343-8d2f-5d51a9877c50.json",
  "deckAnchorHref": "/decks/019de070-7de1-7343-8d2f-5d51a9877c50#slide-14",
  "components": [
    {
      "bbox": {
        "h": 0.6,
        "w": 0.4,
        "x": 0.55,
        "y": 0.2
      },
      "kind": "chart",
      "text": "Cross-Trial Comparison of Constipation and Peripheral Neuropathy",
      "attrs": null,
      "subkind": "bar-horizontal",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f94d4630-338d-4d84-8436-1e3b88cd6f75",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.9,
        "x": 0.05,
        "y": 0.9
      },
      "kind": "disclaimer",
      "text": "Note: CTCAE: Common Terminology Criteria for Adverse Events. The NCI Common Terminology Criteria for Adverse Events is a descriptive terminology which is utilized for Adverse Event (AE) reporting. A grading (severity) scale is provided for each AE term.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5be7d661-0538-440c-bfe2-5412bcb60380",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.3,
        "w": 0.5,
        "x": 0.05,
        "y": 0.5
      },
      "kind": "table",
      "text": "Overview of adverse events in BA3011 Phase 1 trial table",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c2d5f594-1128-4382-8c9f-966aeb7f3f5e",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.7,
        "x": 0.05,
        "y": 0.03
      },
      "kind": "title",
      "text": "BA3011 is Well Tolerated at 1.8mg/kg Q3W or 2Q3W",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "3e096a6f-9847-483b-ae5c-944f57005abc",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Table data",
      "slug": "table-data",
      "agent": null,
      "layer": "slide",
      "matchId": "ce364a1b-5c16-45dc-8f5b-950a83b0fbbe",
      "evidence": "table/data: Overview of adverse events in BA3011 Phase 1 trial table",
      "confidence": 0.7
    }
  ],
  "frameworks": [
    {
      "name": "comparison_frame",
      "slug": null,
      "matchId": "33cd8fc5-4ae4-4063-a4ad-018e8b05ab2d",
      "evidence": "Side-by-side comparison of BA3011 and Enapotamab vedotin safety metrics.",
      "confidence": 0.9
    }
  ],
  "arcBeats": [
    {
      "to": 21,
      "from": 12,
      "beatId": "2003e560-8567-434b-89b9-686dbf1d7731",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Traction",
      "beatSlug": null,
      "evidence": "The document presents traction information on pages 12-21.",
      "position": 3,
      "confidence": 0.8,
      "parentBeatName": null,
      "parentBeatSlug": null
    }
  ],
  "loops": [
    {
      "to": 15,
      "from": 11,
      "name": "Why Now",
      "slug": "15-why-now",
      "bestFor": "Sales pitches, fundraising, requesting immediate budget approval",
      "matchId": "e68a7a0d-6e24-461d-8cb2-101d25fdd683",
      "evidence": "The document presents information on the current market opportunity and the company's progress on pages 11-15.",
      "position": 1,
      "objective": "Why is now the right time to invest in BioAtla?",
      "structure": "The Context (Trends) -> The Trigger Event -> The Window of Opportunity",
      "confidence": 0.6,
      "description": "Create temporal urgency by proving that the window of opportunity is opening or closing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}